Highly Malignant or High-Grade Gliomas (HGG) are tumours of the central nervous system (CNS). They are solid tumours arising from transformed cells called astrocytes of the brain and/or the spinal cord. Since they directly originate from the CNS, they are also called primary CNS tumours, thereby differentiating them from malignant tumours of other organs that have spread (metastasised) to the CNS.
DelveInsight's "High-grade Glioma Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the High-grade Glioma market Size and Share, historical and forecasted epidemiology analysis as well as the High-grade Glioma market trends in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
High-grade Glioma Market Key Facts
According to The Royal Marsden, NHS Foundation Trust, HGG are the most common type of adult brain tumour and although they look the same under the microscope, they may be different biologically. Less than 30 children a year develop high grade glioma in the UK. This is about 8% of all childhood brain and spinal cord tumours.
High-grade Glioma Market Size and Share Analysis
The High-grade Glioma market analysis report helps to build the detailed comprehension of the historic, current and forecasted High-grade Glioma market trends by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of High-grade Glioma market Size and Share analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
High-grade Glioma Epidemiology Forecast
The High-grade Glioma epidemiology analysis covers insights about historical and current High-grade Glioma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
High-grade Glioma Drugs Uptake and Key Market Players
The High-grade Glioma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the High-grade Glioma market or expected to get launched in the market during the study period. The analysis covers High-grade Glioma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the High grade Glioma market is anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players.
Some of the key players involved in developing therapies for High-grade Glioma includes:
BioMimetix
Oncoceutics
Bristol-Myers Squibb
Istari Oncology
Aadi Bioscience
Sumitomo Dainippon Pharma
Novartis Pharmaceuticals
Kazia Therapeutics
And many others.
For more information on High-grade Glioma Market, visit:
https://www.delveinsight.com/report-store/high-grade-glioma-market